RxDoctor Payments Data

Patricia Amedzekor

Family · Center Valley, PANPI 1043943699

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 24 payments — averaging $52.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$341
  • Gilead$233
  • Madrigal Pharmaceuticals$164
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$154
  • Regeneron Healthcare Solutions, Inc.$125
  • E.r. Squibb & Sons, L.L.C.$108
  • plus $141 from 3 others

What the payments were for

  • Food & beverage$1,18193%
  • Education$847%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,265 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$63,615
Medicare patients
594
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$48,849
LinzessLinaclotide54$45,504
Dexlansoprazole DrDexlansoprazole55$14,347
Mesalamine25$11,769
Sucralfate68$8,987
Pantoprazole Sodium483$7,053
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates107$6,937
MotegrityPrucalopride Succinate15$5,345
Omeprazole298$3,645
Famotidine248$3,154
Esomeprazole Magnesium75$2,815
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl141$2,162
CholestyramineCholestyramine (With Sugar)22$1,664
Dicyclomine Hcl58$896
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl47$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$341$94,35369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Center Valley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →